logo
Plus   Neg
Share
Email

Merck: FDA Grants Priority Review To SBLA For Keytruda Plus Chemotherapy

Merck & Co. Inc. (MRK) said Thursday that the U.S. Food and Drug Administration has granted priority review for a new supplemental Biologics License Application or sBLA for KEYTRUDA in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction (GEJ).

This sBLA is based on data from the pivotal Phase 3 KEYNOTE-590 trial. In the trial, KEYTRUDA plus chemotherapy demonstrated significant improvements in the primary endpoints of overall survival (OS) and progression-free survival (PFS), versus chemotherapy in these patients regardless of PD-L1 expression status and tumor histology. KEYTRUDA is Merck's anti-PD-1 therapy.

Merck said it presented the data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

The FDA has set a Prescription Drug User Fee Act date (PDUFA date) as April 13, 2021.

KEYTRUDA is currently approved in the U.S., China and Japan as monotherapy for the second-line treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus.

Merck is continuing to study KEYTRUDA across multiple settings and stages of gastrointestinal cancer - including gastric, hepatobiliary, esophageal, pancreatic, colorectal and anal cancers - through its clinical program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chico's FAS Inc. (CHS) Tuesday reported a wider year-over-year net loss for the fourth quarter. Meanwhile, Kohl's Corp.'s (KSS) fourth-quarter net income grew 29 percent from the previous year. But Abercrombie & Fitch Co.'s (ANF) fourth-quarter net income decreased 1 percent from the prior year. The U.S. Food and Drug Administration has approved the marketing of a new robotically-assisted surgical device (RASD) that can facilitate transvaginal hysterectomy in certain patients using minimally-invasive surgical instruments. The Hominis Surgical System of Memic Innovative Surgery Ltd., the U.S. subsidiary of Israeli biotechnology company memic Ltd., has been granted marketing authorization. Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com. Quatreau is a premium ready-to-drink...
Follow RTT